BioAge Labs (BIOA) investor relations material

Platform and scientific approach

• Focus on leveraging human aging biology to develop therapies for metabolic disease, using a proprietary platform with over 150 million molecular data points and validated by partnerships with Novartis and Lilly.

• Platform includes one of the largest longitudinal human aging datasets, linking molecular data to outcomes like longevity and chronic diseases.

• Lead program targets NLRP3, a pathway implicated in multiple aging-related diseases, with BGE-102 as an oral, brain-penetrant NLRP3 inhibitor.

Clinical data and development plans

• Initial phase I data show BGE-102 normalized CRP in 93% of obese patients with elevated baseline CRP, achieving an 86% reduction from baseline.

• Drug demonstrated best-in-class potency, high CNS penetration, and a favorable safety profile with no dose-limiting toxicity observed.

• Upcoming milestones include full phase I data in the first half of the year, a three-month monotherapy study in the second half, and a DME trial readout in mid-next year.

Cardiovascular and metabolic focus

• BGE-102 aims to reduce cardiovascular risk by lowering CRP, a key biomarker more predictive of MACE outcomes than LDL or Lp(a).

• Three-month monotherapy trial will assess CRP durability, safety, and a broad set of metabolic and inflammatory biomarkers.

• Potential for fixed-dose combinations with other cardiovascular therapies due to oral formulation.